Persistent Systems and TGen collaborate on Bio4D software program; System will provide timely information for oncologists about patient care
May 14, 2012
Persistent Systems (BSE & NSE: PERSISTENT), the leader in
outsourced software product development (OPD) services, and the
Translational Genomics Research Institute (TGen) today announced
that they are developing a high-quality biospecimen management
system called Bio4D.
Initial versions of the Bio4D software, created to manage
biological repositories for genetic and genomic research, have been
used at TGen in the investigation of the underlying causes of
disease.
Now, Persistent Systems and TGen are developing a robust commercial
version of Bio4D to manage the collection, processing, storage,
distribution and analysis of biospecimens, which includes blood,
DNA, and tissue samples, including samples from cancer
biopsies.
Systems such as Bio4D are critical to the advancement of
personalized medicine, in which physicians guide care based on the
genetic profile of each patient.
"Ultimately, tools like Bio4D have the potential to transform the
management of biospecimens and supporting research data in a way
that speeds information between researchers and oncologists," said
Dr. Jeffrey Trent, TGen's President and Research Director.
"Accelerating this process is one more way we can benefit
patients."
A key component of Bio4D will be its ease of use. Unlike generic
LIMS (Laboratory Information Management Systems), Bio4D will be
equipped with features and functionality specifically designed for
the needs of biobank scientists and biospecimen managers.
"Bio4D's design tool greatly simplifies the study and data
collection process, enforces good biospecimen management practices
and compliance with global regulatory requirements," said Peter
Boler, Senior Vice President, Life Sciences and Healthcare,
Persistent Systems. "The solution's web-based technology means
oncologists will be able to access data and system analysis results
in real time from any industry standard Web browsers including IE,
Firefox, Safari, etc. and operating systems such as MS Windows,
MAC, Linux and Unix, making it easier than ever before to mine
information and develop correlative analyses."
Bio4D's search abilities will include clinical and molecular
profile parameters, using a set of filters that could help lead to
the discovery or validation of biomarkers, diagnostics and
therapeutics. Bio4D has the potential to accelerate discovery in
the laboratory, and help translate that information to oncologists
working with clinical patients.
Bio4D is also being designed to help address high levels of
regulatory, ethical and legal scrutiny that surrounds the
biomedical management of biospecimens in association with clinical
and non-clinical trials.
Today's announcement about Bio4D is being made in conjunction with
the International Society for Biological and Environmental
Repositories (ISBER) 2012 Annual Meeting, May 15-18, 2012, at the
Westin Bayshore Hotel in Vancouver, B.C.
About Persistent Systems:
Established in 1990, Persistent Systems (BSE & NSE: PERSISTENT)
is a global company specializing in software product development
services. For more than two decades, Persistent has been an
innovation partner for the world's largest technology brands,
leading enterprises and pioneering start-ups. With a global team of
6,600+ employees, Persistent has 350+ customers spread across North
America, Europe, and Asia. Today, Persistent focuses on developing
best-in-class solutions in four key next-generation technology
areas: Cloud Computing, Mobility, BI& Analytics, Collaboration
across technology, telecommunications, life sciences, consumer
packaged goods, banking & financial services and healthcare
verticals. For more information, please visit:
www.persistentsys.com
Forward-looking and Cautionary Statements:
For risks and uncertainties relating to forward-looking statements,
please visit:
www.persistentsys.com/Portals/0/forward_looking_cautionary_statement.shtml